Identification

Name
Diethylpropion
Accession Number
DB00937  (APRD00919)
Type
Small Molecule
Groups
Approved, Illicit
Description

A appetite depressant considered to produce less central nervous system disturbance than most drugs in this therapeutic category. It is also considered to be among the safest for patients with hypertension. (From AMA Drug Evaluations Annual, 1994, p2290)

Structure
Thumb
Synonyms
  • (±)-diethylpropion
  • 1-phenyl-2-diethylamino-1-propanone
  • 2-(diethylamino)-1-phenyl-1-propanone
  • 2-(diethylamino)propiophenone
  • alpha-Benzoyltriethylamine
  • alpha-Diethylaminopropiophenone
  • Amfepramone
  • Amfépramone
  • Amfepramonum
  • Anfepramona
  • Diethylcathinone
External IDs
DEA No. 1610
Product Ingredients
IngredientUNIICASInChI Key
Diethylpropion hydrochloride19V2PL39NG134-80-5ICFXZZFWRWNZMA-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Diethylpropion HCl Controlled-ReleaseTablet75 mg/1OralA S Medication Solutions1960-11-17Not applicableUs00591 0782 01 nlmimage10 fa45fd5f
Diethylpropion HCl Controlled-ReleaseTablet75 mg/1OralA S Medication Solutions1960-11-172017-06-20Us
Diethylpropion HCl Controlled-ReleaseTablet75 mg/1OralPreferreed Pharmaceuticals Inc.2014-02-12Not applicableUs
Diethylpropion HCl Controlled-ReleaseTablet75 mg/1OralRebel Distributors2008-01-01Not applicableUs
Diethylpropion HCl Controlled-ReleaseTablet75 mg/1Oralbryant ranch prepack2008-01-01Not applicableUs
Diethylpropion HCl Controlled-ReleaseTablet75 mg/1OralNucare Pharmaceuticals, Inc.1960-11-17Not applicableUs
Diethylpropion HCl Controlled-ReleaseTablet75 mg/1OralActavis Pharma Company1960-11-17Not applicableUs
Diethylpropion HCl Controlled-ReleaseTablet75 mg/1OralPhysicians Total Care, Inc.2005-10-03Not applicableUs
Diethylpropion HCl Immediate-ReleaseTablet25 mg/1OralNucare Pharmaceuticals, Inc.1959-08-06Not applicableUs
Diethylpropion HCl Immediate-ReleaseTablet25 mg/1OralPhysicians Total Care, Inc.2004-06-14Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Diethylpropion HCl Controlled-ReleaseTablet75 mg/1OralBlenheim Pharmacal, Inc.2010-03-30Not applicableUs
Diethylpropion HCl Controlled-ReleaseTablet75 mg/1OralKeltman Pharmaceuticals Inc.2010-06-07Not applicableUs
Diethylpropion HCl Immediate-ReleaseTablet25 mg/1OralKeltman Pharmaceuticals Inc.2010-06-07Not applicableUs
Diethylpropion HydrochlorideTablet25 mg/1OralAidarex Pharmaceuticals LLC2011-07-18Not applicableUs
Diethylpropion HydrochlorideTablet25 mg/1OralProficient Rx LP2011-07-18Not applicableUs
Diethylpropion HydrochlorideTablet25 mg/1OralCore Pharma, Llc2008-11-062016-03-16Us
Diethylpropion HydrochlorideTablet25 mg/1OralA S Medication Solutions2010-12-27Not applicableUs
Diethylpropion HydrochlorideTablet25 mg/1Oralbryant ranch prepack2011-07-18Not applicableUs
Diethylpropion HydrochlorideTablet25 mg/1OralLannett Company, Inc.2011-07-18Not applicableUs
Diethylpropion HydrochlorideTablet25 mg/1OralUnit Dose Services2010-12-27Not applicableUs
International/Other Brands
Anorex / Dobesin / Frekentine / Linea / Moderatan / Neobes (Medix) / Nobesine / Prefamone / Regenon (Temmler) / Tepanil / Tylinal
Categories
UNII
Q94YYU22B8
CAS number
90-84-6
Weight
Average: 205.2961
Monoisotopic: 205.146664235
Chemical Formula
C13H19NO
InChI Key
XXEPPPIWZFICOJ-UHFFFAOYSA-N
InChI
InChI=1S/C13H19NO/c1-4-14(5-2)11(3)13(15)12-9-7-6-8-10-12/h6-11H,4-5H2,1-3H3
IUPAC Name
2-(diethylamino)-1-phenylpropan-1-one
SMILES
CCN(CC)C(C)C(=O)C1=CC=CC=C1

Pharmacology

Indication

Used in the management of exogenous obesity as a short-term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction.

Associated Conditions
Pharmacodynamics

Diethylpropion is a sympathomimetic stimulant drug marketed as an appetite suppressant. Chemically, it is the N,N-diethyl analog of cathinone. Its mechanism of action is similar to other appetite suppressants such as sibutramine, phentermine and dextroamphetamine.

Mechanism of action

Diethylpropion is an amphetamine that stimulates neurons to release or maintain high levels of a particular group of neurotransmitters known as catecholamines; these include dopamine and norepinephrine. High levels of these catecholamines tend to suppress hunger signals and appetite. Diethylpropion (through catecholamine elevation) may also indirectly affect leptin levels in the brain. It is theorized that diethylpropion can raise levels of leptin which signal satiety. It is also theorized that increased levels of the catecholamines are partially responsible for halting another chemical messenger known as neuropeptide Y. This peptide initiates eating, decreases energy expenditure, and increases fat storage.

TargetActionsOrganism
ASodium-dependent noradrenaline transporter
inhibitor
Human
ASodium-dependent dopamine transporter
inhibitor
Human
Absorption

Diethylpropion is rapidly absorbed from the GI tract after oral administration.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Extensively metabolized through a complex pathway of biotransformation involving N-dealkylation and reduction. Many of these metabolites are biologically active and may participate in the therapeutic action of diethylpropion.

Route of elimination

Diethylpropion is rapidly absorbed from the GI tract after oral administration and is extensively metabolized through a complex pathway of biotransformation involving N-dealkylation and reduction. Diethylpropion and/or its active metabolites are believed to cross the blood-brain barrier and the placenta. Diethylpropion and its metabolites are excreted mainly by the kidney.

Half life

Using a phosphorescence assay that is specific for basic compounds containing benzoyl group, the plasma half-life of the aminoketone metabolites is estimated to be between 4 to 6 hours.

Clearance
Not Available
Toxicity

The reported oral LD50 for mice is 600 mg/kg, for rats is 250 mg/kg and for dogs is 225 mg/kg. Manifestation of acute overdosage include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, and panic states.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of adverse effects can be increased when Diethylpropion is combined with 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when Diethylpropion is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3-isobutyl-1-methyl-7H-xanthineThe risk or severity of adverse effects can be increased when Diethylpropion is combined with 3-isobutyl-1-methyl-7H-xanthine.Experimental
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when Diethylpropion is combined with 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when Diethylpropion is combined with 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
6-O-benzylguanineThe risk or severity of adverse effects can be increased when Diethylpropion is combined with 6-O-benzylguanine.Investigational
7-DeazaguanineThe risk or severity of adverse effects can be increased when Diethylpropion is combined with 7-Deazaguanine.Experimental
7,9-DimethylguanineThe risk or severity of adverse effects can be increased when Diethylpropion is combined with 7,9-Dimethylguanine.Experimental
8-azaguanineThe risk or severity of adverse effects can be increased when Diethylpropion is combined with 8-azaguanine.Experimental
8-chlorotheophyllineThe risk or severity of adverse effects can be increased when Diethylpropion is combined with 8-chlorotheophylline.Approved
9-DeazaguanineThe risk or severity of adverse effects can be increased when Diethylpropion is combined with 9-Deazaguanine.Experimental
9-MethylguanineThe risk or severity of adverse effects can be increased when Diethylpropion is combined with 9-Methylguanine.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Diethylpropion.Approved, Investigational
AcefyllineThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Acefylline.Experimental
AcepromazineAcepromazine may decrease the stimulatory activities of Diethylpropion.Approved, Vet Approved
AceprometazineDiethylpropion may decrease the sedative and stimulatory activities of Aceprometazine.Approved
AcetazolamideAcetazolamide may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved, Vet Approved
AcetophenazineAcetophenazine may decrease the stimulatory activities of Diethylpropion.Approved
AcrivastineDiethylpropion may decrease the sedative and stimulatory activities of Acrivastine.Approved
AcyclovirThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Acyclovir.Approved
Ajulemic acidThe risk or severity of Tachycardia can be increased when Ajulemic acid is combined with Diethylpropion.Investigational
AlcaftadineDiethylpropion may decrease the sedative and stimulatory activities of Alcaftadine.Approved
AlfentanilDiethylpropion may increase the analgesic activities of Alfentanil.Approved, Illicit
AlimemazineDiethylpropion may decrease the sedative and stimulatory activities of Alimemazine.Approved, Vet Approved
AlmasilateAlmasilate may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved, Experimental
AloglutamolAloglutamol may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved
AlphacetylmethadolDiethylpropion may increase the analgesic activities of Alphacetylmethadol.Experimental, Illicit
AlphaprodineDiethylpropion may increase the analgesic activities of Alphaprodine.Illicit
AluminiumAluminium may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved, Investigational
Aluminium acetoacetateAluminium acetoacetate may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Experimental
Aluminium glycinateAluminium glycinate may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Experimental
Aluminium phosphateAluminium phosphate may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved, Investigational
Aluminum hydroxideAluminum hydroxide may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved, Investigational
AmineptineAmineptine may increase the stimulatory activities of Diethylpropion.Illicit, Withdrawn
AmisulprideAmisulpride may decrease the stimulatory activities of Diethylpropion.Approved, Investigational
AmitriptylineDiethylpropion may decrease the sedative and stimulatory activities of Amitriptyline.Approved
AmitriptylinoxideAmitriptylinoxide may increase the stimulatory activities of Diethylpropion.Approved, Investigational
Ammonium chlorideThe serum concentration of Diethylpropion can be decreased when it is combined with Ammonium chloride.Approved, Investigational, Vet Approved
AmoxapineDiethylpropion may decrease the sedative and stimulatory activities of Amoxapine.Approved
AmperozideAmperozide may decrease the stimulatory activities of Diethylpropion.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Diethylpropion.Approved, Illicit, Investigational
AntazolineDiethylpropion may decrease the sedative and stimulatory activities of Antazoline.Approved
AripiprazoleDiethylpropion may decrease the sedative and stimulatory activities of Aripiprazole.Approved, Investigational
Aripiprazole lauroxilDiethylpropion may decrease the sedative and stimulatory activities of Aripiprazole lauroxil.Approved, Investigational
Ascorbic acidThe serum concentration of Diethylpropion can be decreased when it is combined with Ascorbic acid.Approved, Nutraceutical
AsenapineDiethylpropion may decrease the sedative and stimulatory activities of Asenapine.Approved
AstemizoleDiethylpropion may decrease the sedative and stimulatory activities of Astemizole.Approved, Withdrawn
AtomoxetineThe risk or severity of hypertension can be increased when Atomoxetine is combined with Diethylpropion.Approved
AzaperoneAzaperone may decrease the stimulatory activities of Diethylpropion.Investigational, Vet Approved
AzatadineDiethylpropion may decrease the sedative and stimulatory activities of Azatadine.Approved
AzathioprineThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Azathioprine.Approved
AzelastineDiethylpropion may decrease the sedative and stimulatory activities of Azelastine.Approved
BamifyllineThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Bamifylline.Experimental
BamipineDiethylpropion may decrease the sedative and stimulatory activities of Bamipine.Experimental
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Diethylpropion.Withdrawn
BenperidolBenperidol may decrease the stimulatory activities of Diethylpropion.Approved, Investigational
BenzatropineDiethylpropion may decrease the sedative and stimulatory activities of Benzatropine.Approved
BenzphetamineThe risk or severity of serotonin syndrome can be increased when Benzphetamine is combined with Diethylpropion.Approved, Illicit
BenzquinamideDiethylpropion may decrease the sedative and stimulatory activities of Benzquinamide.Withdrawn
BepotastineDiethylpropion may decrease the sedative and stimulatory activities of Bepotastine.Approved
BetahistineDiethylpropion may decrease the sedative and stimulatory activities of Betahistine.Approved, Investigational
BezitramideDiethylpropion may increase the analgesic activities of Bezitramide.Experimental, Illicit, Withdrawn
BifeprunoxBifeprunox may decrease the stimulatory activities of Diethylpropion.Investigational
BilastineDiethylpropion may decrease the sedative and stimulatory activities of Bilastine.Approved, Investigational
Bismuth subnitrateBismuth subnitrate may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved
BL-1020BL-1020 may decrease the stimulatory activities of Diethylpropion.Investigational
BlonanserinBlonanserin may decrease the stimulatory activities of Diethylpropion.Approved, Investigational
BrexpiprazoleBrexpiprazole may decrease the stimulatory activities of Diethylpropion.Approved, Investigational
BrinzolamideBrinzolamide may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved
BromodiphenhydramineDiethylpropion may decrease the sedative and stimulatory activities of Bromodiphenhydramine.Approved
BromotheophyllineThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Bromotheophylline.Approved
BromperidolBromperidol may decrease the stimulatory activities of Diethylpropion.Approved, Investigational
BrompheniramineDiethylpropion may decrease the sedative and stimulatory activities of Brompheniramine.Approved
BucindololThe risk or severity of adverse effects can be increased when Bucindolol is combined with Diethylpropion.Investigational
BuclizineDiethylpropion may decrease the sedative and stimulatory activities of Buclizine.Approved
BufyllineThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Bufylline.Experimental
BuprenorphineDiethylpropion may increase the analgesic activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButaperazineButaperazine may decrease the stimulatory activities of Diethylpropion.Experimental
ButorphanolDiethylpropion may increase the analgesic activities of Butorphanol.Approved, Illicit, Vet Approved
ButriptylineDiethylpropion may decrease the sedative and stimulatory activities of Butriptyline.Approved
CafedrineThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Cafedrine.Investigational
CaffeineThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Caffeine.Approved
Calcium CarbonateCalcium Carbonate may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved, Investigational
Calcium silicateCalcium silicate may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Experimental
CannabidiolThe risk or severity of Tachycardia can be increased when Cannabidiol is combined with Diethylpropion.Approved, Investigational
CarbinoxamineDiethylpropion may decrease the sedative and stimulatory activities of Carbinoxamine.Approved
CarfentanilDiethylpropion may increase the analgesic activities of Carfentanil.Illicit, Investigational, Vet Approved
CariprazineDiethylpropion may decrease the sedative and stimulatory activities of Cariprazine.Approved, Investigational
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Diethylpropion.Withdrawn
CeliprololThe risk or severity of adverse effects can be increased when Celiprolol is combined with Diethylpropion.Approved, Investigational
CetirizineDiethylpropion may decrease the sedative and stimulatory activities of Cetirizine.Approved
ChlorcyclizineDiethylpropion may decrease the sedative and stimulatory activities of Chlorcyclizine.Approved
ChloropyramineDiethylpropion may decrease the sedative and stimulatory activities of Chloropyramine.Approved
ChlorphenamineDiethylpropion may decrease the sedative and stimulatory activities of Chlorphenamine.Approved
ChlorphenoxamineDiethylpropion may decrease the sedative and stimulatory activities of Chlorphenoxamine.Withdrawn
ChlorphentermineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Diethylpropion.Illicit, Withdrawn
ChlorproethazineChlorproethazine may decrease the stimulatory activities of Diethylpropion.Experimental
ChlorpromazineDiethylpropion may decrease the sedative and stimulatory activities of Chlorpromazine.Approved, Investigational, Vet Approved
ChlorprothixeneDiethylpropion may decrease the sedative and stimulatory activities of Chlorprothixene.Approved, Investigational, Withdrawn
CimetidineDiethylpropion may decrease the sedative and stimulatory activities of Cimetidine.Approved, Investigational
CinnarizineDiethylpropion may decrease the sedative and stimulatory activities of Cinnarizine.Approved, Investigational
ClemastineDiethylpropion may decrease the sedative and stimulatory activities of Clemastine.Approved, Investigational
ClenbuterolThe risk or severity of adverse effects can be increased when Clenbuterol is combined with Diethylpropion.Approved, Investigational, Vet Approved
ClindamycinClindamycin may decrease the stimulatory activities of Diethylpropion.Approved, Vet Approved
ClofedanolDiethylpropion may decrease the sedative and stimulatory activities of Clofedanol.Approved, Withdrawn
ClomipramineClomipramine may increase the stimulatory activities of Diethylpropion.Approved, Investigational, Vet Approved
ClopenthixolClopenthixol may decrease the stimulatory activities of Diethylpropion.Experimental
ClothiapineClothiapine may decrease the stimulatory activities of Diethylpropion.Experimental
ClozapineDiethylpropion may decrease the sedative and stimulatory activities of Clozapine.Approved
CodeineDiethylpropion may increase the analgesic activities of Codeine.Approved, Illicit
CP-945598The risk or severity of Tachycardia can be increased when CP-945598 is combined with Diethylpropion.Investigational
CyamemazineCyamemazine may decrease the stimulatory activities of Diethylpropion.Approved
CyclizineDiethylpropion may decrease the sedative and stimulatory activities of Cyclizine.Approved
CyclobenzaprineCyclobenzaprine may increase the stimulatory activities of Diethylpropion.Approved
CyproheptadineDiethylpropion may decrease the sedative and stimulatory activities of Cyproheptadine.Approved
DapiprazoleDapiprazole may decrease the stimulatory activities of Diethylpropion.Approved
DesipramineDiethylpropion may decrease the sedative and stimulatory activities of Desipramine.Approved, Investigational
DesloratadineDiethylpropion may decrease the sedative and stimulatory activities of Desloratadine.Approved, Investigational
DexbrompheniramineDiethylpropion may decrease the sedative and stimulatory activities of Dexbrompheniramine.Approved
DexchlorpheniramineDiethylpropion may decrease the sedative and stimulatory activities of Dexchlorpheniramine.Experimental, Investigational
Dexchlorpheniramine maleateDiethylpropion may decrease the sedative and stimulatory activities of Dexchlorpheniramine maleate.Approved
DextroamphetamineThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Dextroamphetamine.Approved, Illicit
DextromoramideDiethylpropion may increase the analgesic activities of Dextromoramide.Experimental, Illicit
DextropropoxypheneDiethylpropion may increase the analgesic activities of Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineDiethylpropion may increase the analgesic activities of Dezocine.Approved, Investigational
DibenzepinDibenzepin may increase the stimulatory activities of Diethylpropion.Experimental
DiclofenamideDiclofenamide may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved, Investigational
DihydrocodeineDiethylpropion may increase the analgesic activities of Dihydrocodeine.Approved, Illicit
DihydroetorphineDiethylpropion may increase the analgesic activities of Dihydroetorphine.Experimental, Illicit
DihydromorphineDiethylpropion may increase the analgesic activities of Dihydromorphine.Experimental, Illicit
DimenhydrinateDiethylpropion may decrease the sedative and stimulatory activities of Dimenhydrinate.Approved
DimetacrineDimetacrine may increase the stimulatory activities of Diethylpropion.Approved, Withdrawn
DimetindeneDiethylpropion may decrease the sedative and stimulatory activities of Dimetindene.Approved, Investigational
DimetotiazineDiethylpropion may decrease the sedative and stimulatory activities of Dimetotiazine.Approved
DiphenhydramineDiethylpropion may decrease the sedative and stimulatory activities of Diphenhydramine.Approved, Investigational
DiphenoxylateDiethylpropion may increase the analgesic activities of Diphenoxylate.Approved, Illicit
DiphenylpyralineDiethylpropion may decrease the sedative and stimulatory activities of Diphenylpyraline.Approved, Investigational
DixyrazineDixyrazine may decrease the stimulatory activities of Diethylpropion.Experimental
DobutamineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Diethylpropion.Approved
DopamineThe risk or severity of adverse effects can be increased when Dopamine is combined with Diethylpropion.Approved
DorzolamideDorzolamide may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved
DosulepinDiethylpropion may decrease the sedative and stimulatory activities of Dosulepin.Approved
DoxepinDiethylpropion may decrease the sedative and stimulatory activities of Doxepin.Approved, Investigational
DoxofyllineThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Doxofylline.Approved, Investigational
DoxylamineDiethylpropion may decrease the sedative and stimulatory activities of Doxylamine.Approved, Vet Approved
DPDPEDiethylpropion may increase the analgesic activities of DPDPE.Experimental
DronabinolThe risk or severity of Tachycardia can be increased when Dronabinol is combined with Diethylpropion.Approved, Illicit
DroperidolDroperidol may decrease the stimulatory activities of Diethylpropion.Approved, Vet Approved
EbastineDiethylpropion may decrease the sedative and stimulatory activities of Ebastine.Approved, Investigational
EcopipamEcopipam may decrease the stimulatory activities of Diethylpropion.Investigational
EluxadolineDiethylpropion may increase the analgesic activities of Eluxadoline.Approved, Investigational
EmedastineDiethylpropion may decrease the sedative and stimulatory activities of Emedastine.Approved
EntecavirThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Entecavir.Approved, Investigational
EpanololThe risk or severity of adverse effects can be increased when Epanolol is combined with Diethylpropion.Experimental
EphedrineThe risk or severity of adverse effects can be increased when Ephedrine is combined with Diethylpropion.Approved
EpinastineDiethylpropion may decrease the sedative and stimulatory activities of Epinastine.Approved, Investigational
EpinephrineThe risk or severity of adverse effects can be increased when Epinephrine is combined with Diethylpropion.Approved, Vet Approved
EsmirtazapineDiethylpropion may decrease the sedative and stimulatory activities of Esmirtazapine.Investigational
EtamiphyllineThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Etamiphylline.Experimental
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Diethylpropion.Approved
EthosuximideDiethylpropion can cause a decrease in the absorption of Ethosuximide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
EthoxzolamideEthoxzolamide may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Withdrawn
EthylmorphineDiethylpropion may increase the analgesic activities of Ethylmorphine.Approved, Illicit
EtilefrineThe risk or severity of adverse effects can be increased when Etilefrine is combined with Diethylpropion.Withdrawn
EtorphineDiethylpropion may increase the analgesic activities of Etorphine.Illicit, Vet Approved
FamotidineDiethylpropion may decrease the sedative and stimulatory activities of Famotidine.Approved
FenethyllineThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Fenethylline.Approved
FenoterolThe risk or severity of adverse effects can be increased when Fenoterol is combined with Diethylpropion.Approved, Investigational
FenozoloneThe risk or severity of adverse effects can be increased when Fenozolone is combined with Diethylpropion.Experimental
FentanylThe risk or severity of serotonin syndrome can be increased when Fentanyl is combined with Diethylpropion.Approved, Illicit, Investigational, Vet Approved
FexofenadineDiethylpropion may decrease the sedative and stimulatory activities of Fexofenadine.Approved, Investigational
FluanisoneFluanisone may decrease the stimulatory activities of Diethylpropion.Experimental
FlunarizineDiethylpropion may decrease the sedative and stimulatory activities of Flunarizine.Approved
FlupentixolFlupentixol may decrease the stimulatory activities of Diethylpropion.Approved, Investigational, Withdrawn
FluphenazineFluphenazine may decrease the stimulatory activities of Diethylpropion.Approved
FluspirileneFluspirilene may decrease the stimulatory activities of Diethylpropion.Approved, Investigational
FurafyllineThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Furafylline.Experimental
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Diethylpropion.Approved, Investigational, Vet Approved
GanciclovirThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Ganciclovir.Approved, Investigational
GepefrineThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Gepefrine.Experimental
Glutamic AcidThe serum concentration of Diethylpropion can be decreased when it is combined with Glutamic Acid.Approved, Nutraceutical
GSK-1004723Diethylpropion may decrease the sedative and stimulatory activities of GSK-1004723.Investigational
GuanethidineThe serum concentration of Diethylpropion can be decreased when it is combined with Guanethidine.Approved
GuanineThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Guanine.Experimental
GW842166The risk or severity of Tachycardia can be increased when GW842166 is combined with Diethylpropion.Investigational
HaloperidolHaloperidol may decrease the stimulatory activities of Diethylpropion.Approved
HarmalineThe risk or severity of adverse effects can be increased when Harmaline is combined with Diethylpropion.Experimental
HeroinDiethylpropion may increase the analgesic activities of Heroin.Approved, Illicit, Investigational
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Diethylpropion.Experimental
HydrocodoneThe risk or severity of serotonin syndrome can be increased when Hydrocodone is combined with Diethylpropion.Approved, Illicit
HydromorphoneDiethylpropion may increase the analgesic activities of Hydromorphone.Approved, Illicit
HydrotalciteHydrotalcite may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved, Experimental, Investigational
HydroxyamphetamineThe risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Diethylpropion.Approved
HydroxyzineDiethylpropion may decrease the sedative and stimulatory activities of Hydroxyzine.Approved
HypoxanthineThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Hypoxanthine.Experimental
IbipinabantThe risk or severity of Tachycardia can be increased when Ibipinabant is combined with Diethylpropion.Investigational
IloperidoneDiethylpropion may decrease the sedative and stimulatory activities of Iloperidone.Approved
ImipramineDiethylpropion may decrease the sedative and stimulatory activities of Imipramine.Approved
Imipramine oxideImipramine oxide may increase the stimulatory activities of Diethylpropion.Experimental
IobenguaneDiethylpropion can cause a decrease in the absorption of Iobenguane resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Iofetamine I-123The risk or severity of adverse effects can be increased when Diethylpropion is combined with Iofetamine I-123.Approved
Ioflupane I-123Diethylpropion may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IprindoleIprindole may increase the stimulatory activities of Diethylpropion.Experimental
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Diethylpropion.Withdrawn
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Diethylpropion.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Diethylpropion.Approved, Investigational
IsothipendylDiethylpropion may decrease the sedative and stimulatory activities of Isothipendyl.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Diethylpropion.Approved, Withdrawn
KetobemidoneDiethylpropion may increase the analgesic activities of Ketobemidone.Approved, Investigational
KetotifenDiethylpropion may decrease the sedative and stimulatory activities of Ketotifen.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Diethylpropion.Approved
LafutidineDiethylpropion may decrease the sedative and stimulatory activities of Lafutidine.Investigational
LavoltidineDiethylpropion may decrease the sedative and stimulatory activities of Lavoltidine.Investigational
LevocabastineDiethylpropion may decrease the sedative and stimulatory activities of Levocabastine.Approved, Investigational
LevocetirizineDiethylpropion may decrease the sedative and stimulatory activities of Levocetirizine.Approved
Levomethadyl AcetateDiethylpropion may increase the analgesic activities of Levomethadyl Acetate.Approved, Investigational
LevorphanolDiethylpropion may increase the analgesic activities of Levorphanol.Approved
LincomycinLincomycin may decrease the stimulatory activities of Diethylpropion.Approved, Vet Approved
LinezolidThe risk or severity of hypertension can be increased when Linezolid is combined with Diethylpropion.Approved, Investigational
LisdexamfetamineThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Lisdexamfetamine.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Lisofylline.Investigational
Lithium cationLithium cation may decrease the stimulatory activities of Diethylpropion.Experimental
LobucavirThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Lobucavir.Investigational
LofentanilDiethylpropion may increase the analgesic activities of Lofentanil.Illicit
LofepramineLofepramine may increase the stimulatory activities of Diethylpropion.Experimental
LoratadineDiethylpropion may decrease the sedative and stimulatory activities of Loratadine.Approved, Investigational
LoxapineLoxapine may decrease the stimulatory activities of Diethylpropion.Approved
LumateperoneLumateperone may decrease the stimulatory activities of Diethylpropion.Investigational
LurasidoneLurasidone may decrease the stimulatory activities of Diethylpropion.Approved, Investigational
MagaldrateMagaldrate may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved, Withdrawn
Magnesium carbonateMagnesium carbonate may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved, Investigational
Magnesium hydroxideMagnesium hydroxide may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved, Investigational
Magnesium oxideMagnesium oxide may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved
Magnesium peroxideMagnesium peroxide may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Experimental
Magnesium silicateMagnesium silicate may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved
Magnesium TrisilicateMagnesium Trisilicate may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved
MaprotilineDiethylpropion may decrease the sedative and stimulatory activities of Maprotiline.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Diethylpropion.Withdrawn
MeclizineDiethylpropion may decrease the sedative and stimulatory activities of Meclizine.Approved
MefenorexThe risk or severity of adverse effects can be increased when Mefenorex is combined with Diethylpropion.Experimental
MelitracenMelitracen may increase the stimulatory activities of Diethylpropion.Experimental, Investigational
MelperoneMelperone may decrease the stimulatory activities of Diethylpropion.Approved, Investigational
MephedroneThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Mephedrone.Investigational
MephentermineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Diethylpropion.Approved
MeptazinolDiethylpropion may increase the analgesic activities of Meptazinol.Experimental
MepyramineDiethylpropion may decrease the sedative and stimulatory activities of Mepyramine.Approved, Vet Approved
MequitazineDiethylpropion may decrease the sedative and stimulatory activities of Mequitazine.Approved
MesoridazineMesoridazine may decrease the stimulatory activities of Diethylpropion.Approved, Investigational
MetaraminolThe risk or severity of adverse effects can be increased when Metaraminol is combined with Diethylpropion.Approved, Investigational
MethadoneDiethylpropion may increase the analgesic activities of Methadone.Approved
Methadyl AcetateDiethylpropion may increase the analgesic activities of Methadyl Acetate.Approved, Illicit
MethamphetamineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Diethylpropion.Approved, Illicit
MethanthelineDiethylpropion may decrease the sedative and stimulatory activities of Methantheline.Approved, Investigational
MethapyrileneDiethylpropion may decrease the sedative and stimulatory activities of Methapyrilene.Withdrawn
MethazolamideMethazolamide may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved
MethdilazineDiethylpropion may decrease the sedative and stimulatory activities of Methdilazine.Approved
MethenamineThe serum concentration of Diethylpropion can be decreased when it is combined with Methenamine.Approved, Vet Approved
MethotrimeprazineDiethylpropion may decrease the sedative and stimulatory activities of Methotrimeprazine.Approved, Investigational
MethoxamineThe risk or severity of adverse effects can be increased when Methoxamine is combined with Diethylpropion.Approved, Investigational
MethoxyphenamineThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Methoxyphenamine.Experimental
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Diethylpropion.Approved, Investigational
MetiamideDiethylpropion may decrease the sedative and stimulatory activities of Metiamide.Experimental
MetoclopramideThe risk or severity of serotonin syndrome can be increased when Metoclopramide is combined with Diethylpropion.Approved, Investigational
MianserinDiethylpropion may decrease the sedative and stimulatory activities of Mianserin.Approved, Investigational
MidodrineThe risk or severity of adverse effects can be increased when Midodrine is combined with Diethylpropion.Approved
MidomafetamineThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Midomafetamine.Experimental, Illicit, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Diethylpropion.Approved
MirtazapineDiethylpropion may decrease the sedative and stimulatory activities of Mirtazapine.Approved
MizolastineDiethylpropion may decrease the sedative and stimulatory activities of Mizolastine.Investigational
MMDAThe risk or severity of adverse effects can be increased when Diethylpropion is combined with MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Diethylpropion.Approved, Investigational
MolindoneMolindone may decrease the stimulatory activities of Diethylpropion.Approved
MoperoneMoperone may decrease the stimulatory activities of Diethylpropion.Experimental
MoricizineMoricizine may decrease the stimulatory activities of Diethylpropion.Approved, Investigational, Withdrawn
MorphineDiethylpropion may increase the analgesic activities of Morphine.Approved, Investigational
MosapramineMosapramine may decrease the stimulatory activities of Diethylpropion.Experimental
NabiloneThe risk or severity of Tachycardia can be increased when Nabilone is combined with Diethylpropion.Approved, Investigational
NabiximolsThe risk or severity of Tachycardia can be increased when Nabiximols is combined with Diethylpropion.Approved, Investigational
NalbuphineDiethylpropion may increase the analgesic activities of Nalbuphine.Approved
NaltrexoneDiethylpropion may increase the analgesic activities of Naltrexone.Approved, Investigational, Vet Approved
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Diethylpropion.Withdrawn
NicomorphineDiethylpropion may increase the analgesic activities of Nicomorphine.Experimental
NiperotidineDiethylpropion may decrease the sedative and stimulatory activities of Niperotidine.Experimental, Investigational
NizatidineDiethylpropion may decrease the sedative and stimulatory activities of Nizatidine.Approved
NorepinephrineThe risk or severity of adverse effects can be increased when Norepinephrine is combined with Diethylpropion.Approved
NormethadoneDiethylpropion may increase the analgesic activities of Normethadone.Approved, Illicit
NortriptylineDiethylpropion may decrease the sedative and stimulatory activities of Nortriptyline.Approved
NylidrinThe risk or severity of adverse effects can be increased when Nylidrin is combined with Diethylpropion.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Diethylpropion.Withdrawn
OlanzapineDiethylpropion may decrease the sedative and stimulatory activities of Olanzapine.Approved, Investigational
OlopatadineDiethylpropion may decrease the sedative and stimulatory activities of Olopatadine.Approved
OndansetronThe risk or severity of serotonin syndrome can be increased when Ondansetron is combined with Diethylpropion.Approved
OpipramolOpipramol may increase the stimulatory activities of Diethylpropion.Investigational
OpiumDiethylpropion may increase the analgesic activities of Opium.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Orciprenaline is combined with Diethylpropion.Approved
OrphenadrineDiethylpropion may decrease the sedative and stimulatory activities of Orphenadrine.Approved
OsanetantOsanetant may decrease the stimulatory activities of Diethylpropion.Investigational
OxaprotilineOxaprotiline may increase the stimulatory activities of Diethylpropion.Experimental
OxatomideDiethylpropion may decrease the sedative and stimulatory activities of Oxatomide.Investigational
OxtriphyllineThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Oxtriphylline.Approved
OxycodoneDiethylpropion may increase the analgesic activities of Oxycodone.Approved, Illicit, Investigational
OxymetazolineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Diethylpropion.Approved, Investigational
OxymorphoneDiethylpropion may increase the analgesic activities of Oxymorphone.Approved, Investigational, Vet Approved
OxypertineOxypertine may decrease the stimulatory activities of Diethylpropion.Experimental
PaliperidonePaliperidone may decrease the stimulatory activities of Diethylpropion.Approved
PalmidrolThe risk or severity of Tachycardia can be increased when Palmidrol is combined with Diethylpropion.Experimental, Nutraceutical
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Diethylpropion.Approved
PeldesineThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Peldesine.Experimental, Investigational
PemetrexedThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Pemetrexed.Approved, Investigational
PenciclovirThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Penciclovir.Approved
PenfluridolPenfluridol may decrease the stimulatory activities of Diethylpropion.Experimental
PentazocineDiethylpropion may increase the analgesic activities of Pentazocine.Approved, Vet Approved
PentifyllineThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Pentifylline.Experimental
PentoxifyllineThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Pentoxifylline.Approved, Investigational
PerazinePerazine may decrease the stimulatory activities of Diethylpropion.Approved, Investigational
PerospironePerospirone may decrease the stimulatory activities of Diethylpropion.Approved
PerphenazinePerphenazine may decrease the stimulatory activities of Diethylpropion.Approved
PethidineDiethylpropion may increase the analgesic activities of Pethidine.Approved
PhenazocineDiethylpropion may increase the analgesic activities of Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Diethylpropion.Approved
PhenindamineDiethylpropion may decrease the sedative and stimulatory activities of Phenindamine.Approved
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Diethylpropion.Withdrawn
PheniramineDiethylpropion may decrease the sedative and stimulatory activities of Pheniramine.Approved
PhenmetrazineThe risk or severity of adverse effects can be increased when Phenmetrazine is combined with Diethylpropion.Approved, Illicit
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Diethylpropion.Approved, Investigational
PhenoperidineDiethylpropion may increase the analgesic activities of Phenoperidine.Experimental
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Diethylpropion.Withdrawn
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Diethylpropion.Approved, Illicit
PhenylephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Diethylpropion.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Diethylpropion.Approved, Vet Approved, Withdrawn
PhenytoinThe therapeutic efficacy of Phenytoin can be decreased when used in combination with Diethylpropion.Approved, Vet Approved
PimavanserinPimavanserin may decrease the stimulatory activities of Diethylpropion.Approved, Investigational
PimozidePimozide may decrease the stimulatory activities of Diethylpropion.Approved
PipamperonePipamperone may decrease the stimulatory activities of Diethylpropion.Approved, Investigational
PipotiazinePipotiazine may decrease the stimulatory activities of Diethylpropion.Approved, Investigational
PiritramideDiethylpropion may increase the analgesic activities of Piritramide.Approved, Investigational
PirlimycinPirlimycin may decrease the stimulatory activities of Diethylpropion.Vet Approved
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Diethylpropion.Approved
PitolisantDiethylpropion may decrease the sedative and stimulatory activities of Pitolisant.Approved, Investigational
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Diethylpropion.Withdrawn
PizotifenDiethylpropion may decrease the sedative and stimulatory activities of Pizotifen.Approved
PrenalterolThe risk or severity of adverse effects can be increased when Prenalterol is combined with Diethylpropion.Experimental
ProcaterolThe risk or severity of adverse effects can be increased when Procaterol is combined with Diethylpropion.Approved, Investigational
ProchlorperazineProchlorperazine may decrease the stimulatory activities of Diethylpropion.Approved, Vet Approved
PromazineDiethylpropion may decrease the sedative and stimulatory activities of Promazine.Approved, Vet Approved
PromethazineDiethylpropion may decrease the sedative and stimulatory activities of Promethazine.Approved, Investigational
PropentofyllineThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Propentofylline.Investigational
PropericiazinePropericiazine may decrease the stimulatory activities of Diethylpropion.Approved, Investigational
PropiomazineDiethylpropion may decrease the sedative and stimulatory activities of Propiomazine.Approved
PropiopromazinePropiopromazine may decrease the stimulatory activities of Diethylpropion.Vet Approved
ProthipendylProthipendyl may decrease the stimulatory activities of Diethylpropion.Investigational
ProtriptylineProtriptyline may increase the stimulatory activities of Diethylpropion.Approved
ProxyphyllineThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Proxyphylline.Experimental
PseudoephedrineThe risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Diethylpropion.Approved
QuetiapineDiethylpropion may decrease the sedative and stimulatory activities of Quetiapine.Approved
QuifenadineDiethylpropion may decrease the sedative and stimulatory activities of Quifenadine.Experimental
QuinupramineQuinupramine may increase the stimulatory activities of Diethylpropion.Experimental
RacepinephrineThe risk or severity of adverse effects can be increased when Racepinephrine is combined with Diethylpropion.Approved
RacloprideRaclopride may decrease the stimulatory activities of Diethylpropion.Investigational
RanitidineDiethylpropion may decrease the sedative and stimulatory activities of Ranitidine.Approved
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Diethylpropion.Approved
RemifentanilDiethylpropion may increase the analgesic activities of Remifentanil.Approved
RemoxiprideRemoxipride may decrease the stimulatory activities of Diethylpropion.Approved, Withdrawn
ReserpineReserpine may decrease the stimulatory activities of Diethylpropion.Approved, Investigational
RimonabantThe risk or severity of Tachycardia can be increased when Rimonabant is combined with Diethylpropion.Approved, Investigational
RisperidoneDiethylpropion may decrease the sedative and stimulatory activities of Risperidone.Approved, Investigational
RitanserinRitanserin may decrease the stimulatory activities of Diethylpropion.Investigational
RitobegronThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Ritodrine is combined with Diethylpropion.Approved, Investigational
Roxatidine acetateDiethylpropion may decrease the sedative and stimulatory activities of Roxatidine acetate.Approved, Investigational
RP-5063RP-5063 may decrease the stimulatory activities of Diethylpropion.Investigational
RupatadineDiethylpropion may decrease the sedative and stimulatory activities of Rupatadine.Approved
SafinamideThe risk or severity of adverse effects can be increased when Safinamide is combined with Diethylpropion.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Diethylpropion.Withdrawn
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Diethylpropion.Approved, Investigational, Vet Approved
SertindoleSertindole may decrease the stimulatory activities of Diethylpropion.Approved, Investigational, Withdrawn
SLV319The risk or severity of Tachycardia can be increased when SLV319 is combined with Diethylpropion.Investigational
Sodium bicarbonateSodium bicarbonate may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved
SufentanilDiethylpropion may increase the analgesic activities of Sufentanil.Approved, Investigational
SulpirideSulpiride may decrease the stimulatory activities of Diethylpropion.Approved, Investigational
SultoprideSultopride may decrease the stimulatory activities of Diethylpropion.Experimental
SurinabantThe risk or severity of Tachycardia can be increased when Surinabant is combined with Diethylpropion.Investigational
SynephrineThe risk or severity of adverse effects can be increased when Synephrine is combined with Diethylpropion.Experimental
TapentadolDiethylpropion may increase the analgesic activities of Tapentadol.Approved
Tedizolid phosphateTedizolid phosphate may increase the hypertensive activities of Diethylpropion.Approved
TerbutalineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Diethylpropion.Approved
TerfenadineDiethylpropion may decrease the sedative and stimulatory activities of Terfenadine.Approved, Withdrawn
TetrahydropalmatineTetrahydropalmatine may decrease the stimulatory activities of Diethylpropion.Investigational
TetryzolineThe risk or severity of adverse effects can be increased when Tetryzoline is combined with Diethylpropion.Approved
TheobromineThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Theobromine.Approved, Investigational
TheodrenalineThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Theodrenaline.Investigational
ThiazinamThiazinam may decrease the stimulatory activities of Diethylpropion.Experimental
ThiethylperazineThiethylperazine may decrease the stimulatory activities of Diethylpropion.Withdrawn
ThiopropazateThiopropazate may decrease the stimulatory activities of Diethylpropion.Experimental
ThioproperazineThioproperazine may decrease the stimulatory activities of Diethylpropion.Approved
ThioridazineThioridazine may decrease the stimulatory activities of Diethylpropion.Approved, Withdrawn
ThiothixeneThiothixene may decrease the stimulatory activities of Diethylpropion.Approved
ThonzylamineDiethylpropion may decrease the sedative and stimulatory activities of Thonzylamine.Approved
TianeptineTianeptine may increase the stimulatory activities of Diethylpropion.Approved, Investigational
TiaprideTiapride may decrease the stimulatory activities of Diethylpropion.Approved, Investigational
TilidineDiethylpropion may increase the analgesic activities of Tilidine.Experimental
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Diethylpropion.Approved
TramadolDiethylpropion may increase the analgesic activities of Tramadol.Approved, Investigational
TramazolineThe risk or severity of adverse effects can be increased when Tramazoline is combined with Diethylpropion.Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Diethylpropion.Approved, Investigational
TrazodoneDiethylpropion may decrease the sedative and stimulatory activities of Trazodone.Approved, Investigational
TretoquinolThe risk or severity of adverse effects can be increased when Tretoquinol is combined with Diethylpropion.Experimental
TrifluoperazineTrifluoperazine may decrease the stimulatory activities of Diethylpropion.Approved, Investigational
TrifluperidolTrifluperidol may decrease the stimulatory activities of Diethylpropion.Experimental
TriflupromazineTriflupromazine may decrease the stimulatory activities of Diethylpropion.Approved, Vet Approved
TrimipramineDiethylpropion may decrease the sedative and stimulatory activities of Trimipramine.Approved
TripelennamineDiethylpropion may decrease the sedative and stimulatory activities of Tripelennamine.Approved, Vet Approved
TriprolidineDiethylpropion may decrease the sedative and stimulatory activities of Triprolidine.Approved
TritoqualineDiethylpropion may decrease the sedative and stimulatory activities of Tritoqualine.Approved
TyramineThe risk or severity of adverse effects can be increased when Tyramine is combined with Diethylpropion.Investigational, Nutraceutical
Uric AcidThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Uric Acid.Experimental, Investigational
ValaciclovirThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Valaciclovir.Approved, Investigational
ValganciclovirThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Valganciclovir.Approved, Investigational
ValomaciclovirThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Valomaciclovir.Investigational
VeraliprideVeralipride may decrease the stimulatory activities of Diethylpropion.Experimental
WIN 55212-2The risk or severity of Tachycardia can be increased when WIN 55212-2 is combined with Diethylpropion.Experimental
XanthineThe risk or severity of adverse effects can be increased when Diethylpropion is combined with Xanthine.Experimental
ZiprasidoneDiethylpropion may decrease the sedative and stimulatory activities of Ziprasidone.Approved
ZotepineZotepine may decrease the stimulatory activities of Diethylpropion.Approved, Investigational, Withdrawn
ZuclopenthixolDiethylpropion may decrease the sedative and stimulatory activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take without regard to meals.

References

Synthesis Reference

Schutte, J.; U.S. Patent 3,001,910; September 26, 1961; assigned to Firma Ternmler-Werke (W. Germany).

US3001910
General References
  1. Adan RA, Vanderschuren LJ, la Fleur SE: Anti-obesity drugs and neural circuits of feeding. Trends Pharmacol Sci. 2008 Apr;29(4):208-17. doi: 10.1016/j.tips.2008.01.008. Epub 2008 Mar 18. [PubMed:18353447]
  2. Arias HR, Santamaria A, Ali SF: Pharmacological and neurotoxicological actions mediated by bupropion and diethylpropion. Int Rev Neurobiol. 2009;88:223-55. doi: 10.1016/S0074-7742(09)88009-4. [PubMed:19897080]
External Links
Human Metabolome Database
HMDB0015072
KEGG Drug
D07444
KEGG Compound
C06954
PubChem Compound
7029
PubChem Substance
46506622
ChemSpider
6762
ChEBI
4530
ChEMBL
CHEMBL1194666
Therapeutic Targets Database
DAP001452
PharmGKB
PA164778098
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Diethylpropion
ATC Codes
A08AA03 — Amfepramone
FDA label
Download (114 KB)
MSDS
Download (103 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4TerminatedTreatmentBMI >30 kg/m21

Pharmacoeconomics

Manufacturers
  • Sanofi aventis us llc
  • Watson pharmaceuticals
  • 3m pharmaceuticals inc
  • Corepharma llc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Tg united labs llc
  • Ucb inc
  • Watson laboratories inc
Packagers
  • Aidarex Pharmacuticals LLC
  • Apotheca Inc.
  • A-S Medication Solutions LLC
  • Bryant Ranch Prepack
  • Calvin Scott and Co. Inc.
  • Carlisle Laboratories Inc.
  • Corepharma LLC
  • Darby Dental Supply Co. Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Keltman Pharmaceuticals Inc.
  • Lake Erie Medical and Surgical Supply
  • Landmark Chemical Co.
  • Macnary Ltd.
  • Merrell Pharmaceuticals Inc.
  • Nucare Pharmaceuticals Inc.
  • Patheon Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepak Systems Inc.
  • Qualitest
  • Quality Research Pharmaceutical Inc.
  • Rebel Distributors Corp.
  • Southwood Pharmaceuticals
  • United Research Laboratories Inc.
  • Watson Pharmaceuticals
Dosage forms
FormRouteStrength
TabletOral75 mg/1
TabletOral25 mg/1
Tablet, extended releaseOral75 mg/1
Capsule, extended releaseOral75 mg
TabletOral25 mg
Tablet, extended releaseOral75 mg
Prices
Unit descriptionCostUnit
Diethylpropion HCl CR 75 mg 24 Hour tablet1.0USD tablet
Tenuate 25 mg tablet0.67USD tablet
Diethylpropion 25 mg tablet0.52USD tablet
Diethylpropion HCl 25 mg tablet0.29USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)168Schutte, J.; U.S. Patent 3,001,910; September 26, 1961; assigned to Firma Ternmler-Werke (W. Germany).
logP2.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.22 mg/mLALOGPS
logP2.8ALOGPS
logP2.7ChemAxon
logS-2.2ALOGPS
pKa (Strongest Acidic)17.43ChemAxon
pKa (Strongest Basic)7.44ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area20.31 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity63.88 m3·mol-1ChemAxon
Polarizability24.12 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9354
Caco-2 permeable+0.8532
P-glycoprotein substrateNon-substrate0.5328
P-glycoprotein inhibitor INon-inhibitor0.8859
P-glycoprotein inhibitor IINon-inhibitor0.9157
Renal organic cation transporterNon-inhibitor0.6691
CYP450 2C9 substrateNon-substrate0.8022
CYP450 2D6 substrateNon-substrate0.6551
CYP450 3A4 substrateNon-substrate0.6339
CYP450 1A2 substrateInhibitor0.7358
CYP450 2C9 inhibitorNon-inhibitor0.952
CYP450 2D6 inhibitorNon-inhibitor0.7815
CYP450 2C19 inhibitorNon-inhibitor0.8088
CYP450 3A4 inhibitorNon-inhibitor0.9438
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6602
Ames testNon AMES toxic0.9326
CarcinogenicityCarcinogens 0.5877
BiodegradationNot ready biodegradable0.9236
Rat acute toxicity2.6791 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8475
hERG inhibition (predictor II)Non-inhibitor0.8179
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0udi-9600000000-6ee5a640521355e9e385
Mass Spectrum (Electron Ionization)MSsplash10-0udi-2900000000-43214c102b76f59ba4d1
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as alkyl-phenylketones. These are aromatic compounds containing a ketone substituted by one alkyl group, and a phenyl group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbonyl compounds
Direct Parent
Alkyl-phenylketones
Alternative Parents
Phenylpropanes / Benzoyl derivatives / Aryl alkyl ketones / Alpha-amino ketones / Trialkylamines / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
Alkyl-phenylketone / Phenylpropane / Benzoyl / Aryl alkyl ketone / Benzenoid / Monocyclic benzene moiety / Alpha-aminoketone / Tertiary aliphatic amine / Tertiary amine / Hydrocarbon derivative
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
tertiary amine, aromatic ketone (CHEBI:4530)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Norepinephrine:sodium symporter activity
Specific Function
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A2
Uniprot ID
P23975
Uniprot Name
Sodium-dependent noradrenaline transporter
Molecular Weight
69331.42 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Arias HR, Santamaria A, Ali SF: Pharmacological and neurotoxicological actions mediated by bupropion and diethylpropion. Int Rev Neurobiol. 2009;88:223-55. doi: 10.1016/S0074-7742(09)88009-4. [PubMed:19897080]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Monoamine transmembrane transporter activity
Specific Function
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A3
Uniprot ID
Q01959
Uniprot Name
Sodium-dependent dopamine transporter
Molecular Weight
68494.255 Da
References
  1. Yu H, Rothman RB, Dersch CM, Partilla JS, Rice KC: Uptake and release effects of diethylpropion and its metabolites with biogenic amine transporters. Bioorg Med Chem. 2000 Dec;8(12):2689-92. [PubMed:11131159]
  2. Arias HR, Santamaria A, Ali SF: Pharmacological and neurotoxicological actions mediated by bupropion and diethylpropion. Int Rev Neurobiol. 2009;88:223-55. doi: 10.1016/S0074-7742(09)88009-4. [PubMed:19897080]

Drug created on June 13, 2005 07:24 / Updated on August 02, 2018 07:42